Jayne B. Hart - Feb 28, 2022 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role
Chief People Officer
Signature
By: Nathan A. Smith For: Jayne B. Hart
Stock symbol
MYGN
Transactions as of
Feb 28, 2022
Transactions value $
-$10,710
Form type
4
Date filed
3/1/2022, 03:55 PM
Previous filing
Feb 18, 2022
Next filing
Mar 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Options Exercise $168K +7K +4.22% $23.98 173K Feb 28, 2022 Direct F1, F2
transaction MYGN Common Stock Sale -$175K -7K -4.05% $25.00 166K Feb 28, 2022 Direct F1
transaction MYGN Common Stock Options Exercise $83.9K +3.5K +2.11% $23.98 169K Feb 28, 2022 Direct F1, F2
transaction MYGN Common Stock Sale -$87.5K -3.5K -2.07% $25.00 166K Feb 28, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYGN Incentive Stock Option (right to buy) Options Exercise $0 -3.5K -100% $0.00* 0 Feb 28, 2022 Common Stock 3.5K $23.98 Direct F1, F3
transaction MYGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -7K -100% $0.00* 0 Feb 28, 2022 Common Stock 7K $23.98 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 Represents shares of common stock received upon exercise of a stock option award.
F3 The shares subject to this option are fully vested and exercisable.